论文部分内容阅读
经肝动脉化疗栓塞术(TAE)治疗原发性和转移性肝癌已广泛应用于临床,尤其对中晚期肝癌已被公认为是首选治疗方法。虽然随着手术切除方法的改进,切除率的明显上升,然而复发率仍然很高,一方面由于肝癌症状的隐袭性,就诊时病期较晚。另一方面肿瘤本身生物学特性,如多中心发生,早期发生肝内转移等。近年来随着介入技术的蓬勃发展,肝动脉灌注化疗栓塞术,可以有效的控制肿瘤的生长,延长患者的生存期,提高患者的生活质量。
Transcatheter arterial chemoembolization (TAE) in the treatment of primary and metastatic liver cancer has been widely used in clinical practice, especially in advanced liver cancer has been recognized as the preferred method of treatment. Although with the improvement of surgical resection, resection rate increased significantly, however, the recurrence rate is still high, on the one hand due to the implicit nature of liver cancer symptoms, treatment time is late. On the other hand the biological characteristics of the tumor itself, such as polycentric, early occurrence of intrahepatic metastasis. In recent years, with the vigorous development of interventional technology, hepatic arterial chemoembolization can effectively control tumor growth, prolong the survival of patients and improve the quality of life of patients.